Clozapine vs Paliperidone palmitate (Invega Trinza)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Clozapine

Marketed by HLS Therapeutics Inc.

Approved in Schizophreniasmall molecule
Weak signal

NCT00250575 · Phase 3 · completed

The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.

Next expected readout: April 2027 · NCT04580134 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)

Result source: NCT03510325

Paliperidone palmitate (Invega Trinza)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule (palmitate ester prodrug, long-acting injectable suspension)
Weak signal

NCT02713282 · Phase 3 · completed

This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)

Result source: NCT04072575

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointClozapinePaliperidone palmitate (Invega Trinza)
PANSS total, change—Not posted · NCT00649844-1.8 vs -1.6vs PP3Mwk 52 · n 473NCT03345342
CGI-S, change—Not posted · NCT006498440 vs 0vs PP3Mwk 52 · n 475NCT03345342
2 other results
PANSS response—Not posted · NCT00649844—Not posted · NCT02713282
PSP, change—Not posted · NCT006498441 vs 1.1vs PP3Mwk 52 · n 473NCT03345342
2 other results
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
Relapse (% of patients)—Not posted · NCT00649844—Not posted · NCT02713282

PANSS total, change

Clozapine
—Not posted · NCT00649844
Paliperidone palmitate (Invega Trinza)
-1.8 vs -1.6vs PP3Mwk 52 · n 473NCT03345342

CGI-S, change

Clozapine
—Not posted · NCT00649844
Paliperidone palmitate (Invega Trinza)
0 vs 0vs PP3Mwk 52 · n 475NCT03345342
2 other results

PANSS response

Clozapine
—Not posted · NCT00649844
Paliperidone palmitate (Invega Trinza)
—Not posted · NCT02713282

PSP, change

Clozapine
—Not posted · NCT00649844
Paliperidone palmitate (Invega Trinza)
1 vs 1.1vs PP3Mwk 52 · n 473NCT03345342
2 other results
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702

Relapse (% of patients)

Clozapine
—Not posted · NCT00649844
Paliperidone palmitate (Invega Trinza)
—Not posted · NCT02713282
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clozapine: 3 of 4 rows · Paliperidone palmitate (Invega Trinza): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClozapinePaliperidone palmitate (Invega Trinza)
Dropout rate
41.7%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT00498550 · Phase 4 · registry result, not featured evidence
17.2%
NCT02404155 · Phase na · registry result, not featured evidence
—Double-blind PP6Mb
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
13.5%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
—
NCT01529515 · Phase 3
—Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT00498550 · Phase 4 · registry result, not featured evidence
—
NCT02404155 · Phase na · registry result, not featured evidence
—Double-blind PP6Mb
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
3.9%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
—
NCT01529515 · Phase 3
—Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Serious AEs
13%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
26.7%
NCT00498550 · Phase 4 · registry result, not featured evidence
6.9%
NCT02404155 · Phase na · registry result, not featured evidence
5%Double-blind PP6Mb
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
5.5%Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
4.5%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
2.5%
NCT01529515 · Phase 3
12.8%Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
5.3%Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
2%Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
other-sialorrhea 43.5%
weight gain 30.4%
sedation 21.7%
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
gastrointestinal disorder - other: hypersalivation 66.7%
somnolence 60%
weight gain 40%
NCT00498550 · Phase 4 · registry result, not featured evidence
salivation 68.2%
sedation 52.9%
malaise 52.6%
NCT02404155 · Phase na · registry result, not featured evidence
b
weight increased 8.4%
injection site pain 7.7%
headache 6.7%
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
nasopharyngitis 3.7%
upper respiratory tract infection 0.9%
headache 0%
NCT03345342 · Phase 3 · Schizophrenia · phase 3
700 or 1000 mg eq
headache 13.5%
blood prolactin increased 10.7%
hyperprolactinaemia 7.3%
NCT04072575 · Phase 3 · combination
headache 8.8% (placebo 4.1%)
weight increased 8.8% (placebo 3.4%)
anxiety 8.1% (placebo 10.3%)
NCT01529515 · Phase 3
weight increased 28.2%
akathisia 9%
headache 9%
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
weight increased 15.8%
anxiety 10.5%
insomnia 10.5%
NCT02431702 · Phase 3 · registry result, not featured evidence
weight increased 14.3%
insomnia 10.2%
nasopharyngitis 6.1%
NCT02431702 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clozapine

Cannabis Use Intensity Joints Per 2.36 vs 2.35 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 10.21 weeks as posted
Cannabis Use Frequency Days Per 0.14 vs 0.15 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 4.26 days as posted
Cannabis Use Joints Per 0.02 per week
absolute value · per week
No placebo or comparator arm
NCT00498550 · Phase 4 · registry result, not featured evidence

Paliperidone palmitate (Invega Trinza)

Time to Relapse NA vs NA PP3M months @ 52wk
time to event · months
NCT03345342 · Phase 3 · Schizophrenia · phase 3
PANSS Total -1.8 vs -1.6 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
CGI-S 0 vs 0 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 2 more results
-0.2 vs -0.3 Oral Antipsychotics score
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
-0.7 vs -0.7 Oral Antipsychotics score
NCT02431702 · Phase 3 · registry result, not featured evidence
PSP 1 vs 1.1 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 2 more results
2.5 vs 2.9 Oral Antipsychotics score @ 39.1wk
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 7 Oral Antipsychotics score @ 78.2wk
NCT02431702 · Phase 3 · registry result, not featured evidence
Symptomatic Remission 66.3% (n=478) vs 70.1% (n=224) PP3M @ 52wk
responder rate · % of participants
NCT03345342 · Phase 3 · Schizophrenia · phase 3
Relapse 3.9% (n=178) @ 104wk700 or 1000 mg eq
event count · % of participants
No placebo or comparator arm
NCT04072575 · Phase 3 · combination · converted to % from 7 Participants as posted
CGI-S 0 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
PSP 0.5 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
PANSS Total 0.7 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
Time to Relapse Median NA vs 12.98 placebo months @ 60wk
time to event · months
NCT01529515 · Phase 3
PANSS Total -0.5 vs 6.7 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3
CGI-S 0.1 vs 0.4 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3

+ 11 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Paliperidone palmitate (Invega Trinza)'s landscape